Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma

Official Title

Phase 1, Multicentre, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma

Summary:

This is a Phase 1, multi-centre, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.

Trial Description

Primary Outcome:

  • Maximum Tolerated Dose (MTD)
Secondary Outcome:
  • Evaluate incidence and severity of AEs, serious AEs, TRPH-222-related AEs, AEs leading to death or discontinuation from treatment
  • Tumour Activity
  • TRPH-222 Pharmacokinetics (PK)
  • TRPH-222 Pharmacokinetics (PK)
  • TRPH-222 Pharmacokinetics (PK)
  • TRPH-222 Pharmacokinetics (PK)
  • TRPH-222 Pharmacokinetics (PK)
  • TRPH-222 Pharmacokinetics (PK)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society